Zymergen Inc. (ZY) Q3 2021 Earnings Call Transcript
ZY earnings call for the period ending September 30, 2021.
Source: fool.com
Page 14 - Jay Flatley News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Jay Flatley. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Jay Flatley Today - Breaking & Trending Today
David Cameron landed US genomics giant Illumina a £123m contract 'after writing to Hancock'
David Cameron, a paid adviser for US biotech gene-sequencing company Illumina, told Matt Hancock he 'strongly endorsed' the firm's invitation to the then-Health Secretary in April 2019.
Source: dailymail.co.uk
Synthetic Biology Company Zymergen Plunges 68% After Saying Product Revenue Will Be 'Immaterial' in 2022, Removing CEO – NBC 7 San Diego
By Ari Levy, CNBC • Updated 5 hours ago Mark Neuling | CNBC Zymergen went public at $31 a share in April and traded as high as $48.50, valuing the company at $4.8 billion. The stock sank to $11.07 after hours on Tuesday, leaving its market cap at just over $1 billion. The company has yet to start generating product sales and said it now expects revenue from its products to be "immaterial" through 2022. A little more than three months after pricing its IPO at the top of its expected range and soaring out of the gate, Zymergen is warning investors that revenue from its experimenta...
Source: nbcsandiego.com
Synthetic Biology Company Zymergen Plunges 68% After Saying Product Revenue Will Be 'Immaterial' in 2022, Removing CEO – NBC10 Philadelphia
By Ari Levy, CNBC • Updated on August 3, 2021 at 8:15 pm Mark Neuling | CNBC Zymergen went public at $31 a share in April and traded as high as $48.50, valuing the company at $4.8 billion. The stock sank to $11.07 after hours on Tuesday, leaving its market cap at just over $1 billion. The company has yet to start generating product sales and said it now expects revenue from its products to be "immaterial" through 2022. A little more than three months after pricing its IPO at the top of its expected range and soaring out of the gate, Zymergen is warning investors that revenue fro...
Source: nbcphiladelphia.com
Zymergen Provides Business Update
Zymergen Provides Business Update Zymergen Inc. Jay Flatley, Chairman of the Board, Appointed Acting CEO; Josh Hoffman to Step Down Conference Call to be Held at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time Today EMERYVILLE, Calif., Aug. 03, 2021 (GLOBE NEWSWIRE) -- Zymergen Inc. (“Zymergen” or the “Company”), today provided a business update regarding its commercial product pipeline and financial forecast. Zymergen recently became aware of issues with its commercial product pipeline that will impact the Company’s delivery timeline and revenue projections. Accordingly, the ...
Source: globenewswire.com